BIONEUTRAL

Revenue Growth (YoY)

1.1%

Higher than 26% of Healthcare sector peers

Updated 414h ago

Sector Performance

26th percentile

BIO

1.1%

Sector Median

6.2%

Sector Avg

4.2%

📊

Deep Analysis

Bio-Rad Laboratories’ current revenue growth year-over-year (YoY)—the percentage increase in sales compared to the same quarter last year—is 1.1%.

This is well below the Healthcare sector median of 6.2%, placing the company at the 28th percentile among its peers. The trend direction over the last eight quarters is not available, but the most recent YoY figure of 1.1% marks a decline from the prior quarter’s 3.9%, and the quarter-over-quarter change in the metric itself is a drop of 71.8%. The combination of a low revenue growth level and a sharp downward trend suggests limited near-term momentum, raising the risk that earnings may disappoint. This weak performance supports the overall NEUTRAL verdict, as

Frequently Asked Questions

What does the Revenue Growth (YoY) tell investors about BIO?

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.

How is the Revenue Growth (YoY) calculated?

Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.

How does BIO's Revenue Growth (YoY) compare to its sector?

BIO's Revenue Growth (YoY) of 1.1% compares to a Healthcare sector median of 6.2%, placing it in the 26th percentile.

Who are BIO's closest peers by Revenue Growth (YoY)?

The closest Healthcare peers by Revenue Growth (YoY) include: ALGN (6.2%), AMGN (5.8%), CPRX (5.6%), ABT (7.8%), ZBH (9.3%).

The Formula

(Revenue_t - Revenue_t-4) / Revenue_t-4

Why It Matters

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.